Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1346-1352

  Vencken, P M L H ^a   Kriege, M ^a   Hoogwerf, D ^a   Beugelink, S ^a   van der Burg, M E L ^a   Hooning, M J ^a   Berns, E M ^a   Jager, A ^a   Collee M ^a   Burger, C W ^a   Seynaeve, C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BRCA; Chemotherapy; Ovarian Cancer; Response; Survival

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; PACLITAXEL; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; DRUG RESPONSE; FAMILY HISTORY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

EID: 79955390596     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq628     Document Type: Article

References (29)

1. Vernooij F, Heintz AP, Witteveen E et al. Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study. J Natl Cancer Inst 2008; 100(6): 399-406.
2. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trail in patients with suboptimal stage III/IV ovarian cancer. Semin Oncol 1996; 23 (5 Suppl 12): 40-47.
3. Tan DS, Rothermundt C, Thomas K et al. BCRAness Syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26(34): 5530-5536.
4. Risch HA, Mc Laughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and 2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001; 68(3): 700-710.
5. Kramer JL, Velazquez IA, Chen BE et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005; 23(34): 8629-8635.
6. Kauff ND, Domcheck SM, Friebel TM et al. Risk reducing salpingo-oophorectomy for the prevention of f BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26(8): 1331-1337.
7. Quinn JE, Carser JE, James CR et al. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009; 113(1): 134-142.
8. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62(3): 676-689.
9. Thompson D, Easton D. Variation in cancer risks by mutation position in BRCA2 mutation carriers. Am J Hum Genet 2001; 68(2): 410-419.
10. Antoniou A, Pharoah PD, Narod S et al. Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72(5): 1117-1130.
11. King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302(5645): 643-646.
12. Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26(1): 20-25.
13. Kauf ND. Is it time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer. J Clin Oncol 2008; 26(1): 9-10.
14. Cass I, Baldwin RL, Varakey T et al. Improved survival in women with BRCAassociated ovarian carcinomata. Cancer 2003; 97: 2187-2195.
15. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283(17): 2260-2265.
16. Ben David Y, Chetrit A, Hirsh-Yechezkel G et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002; 20(2): 463-466.
17. Safra T. Hereditary ovarian cancer; biology, response to chemotherapy and prognosis. Womens Health 2009; 5(5): 543-553.
18. Tagliaferri P, Ventura M, Baudi F et al. BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? J Ovarian Res 2009; 13: 2-14.
19. van der Hout AH, van den Ouweland AM, van der Luijt RB et al. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat 2006; 27: 654-666.
20. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917-921.
21. Levine DA, Federici MG, Reuter VE et al. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer 2002; 85: 431-434.
22. Jazaeri AA. Molecular profiles of hereditary epithelial ovarian cancers and the implications for the biology of this disease. Mol Oncol 2009; 3(2): 151-156.
23. Pal T, Permuth-Wey J, Kapoor R et al. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer 2007; 6(1): 113-119.
24. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335(19): 1413-1416.
25. Evans GR, Gaarenstroom KN, Stirling D et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2008; 46(9): 593-597.
26. Eisenhaeur EA, Therasse P, Bogaerst J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
27. Oh Park J, Il See S, Young Song S et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003; 33(10): 533-537.
28. Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep 2008; 10(6): 519-523.
29. Russo A, Calo V, Bruno L et al. Hereditary ovarian cancer. Crit Rev Oncol Hematol 2009; 69(1): 28-44.